Neoplasm.News

KRAS inhibitor × Thoracic × Clear all

2 Announcements

FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC

Drug: Krazati (adagrasib) · KRAS inhibitor
Condition: Thoracic

FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC

Drug: Lumakras (sotorasib) · KRAS inhibitor
Condition: Thoracic